ALK Inhibitor Therapy

ALK-positive lung cancer is treated with a tablet taken at home. For many patients it works for years.

The biopsy shows lung cancer, and the molecular report adds a line that changes everything after it. ALK-positive. A small share of lung cancers are driven by a single broken gene called ALK. Most of these patients never smoked. Tablets that switch the gene off shrink the cancer in eight patients out of ten, and the newest of them keep it controlled far longer than chemotherapy ever did, in people who are frequently still working and raising children. In the CROWN trial, 60 percent of patients taking lorlatinib were alive without the cancer growing five years later, against 8 percent on the first-generation drug. In ALEX, alectinib cut the chance of the cancer growing in the brain from 45 to 12 percent. And since 2024 the same approach has moved to early disease, where two years of alectinib after surgery left 94 percent free of cancer at two years, against 63 percent after chemotherapy. This page explains the test, the drugs, how the first one is chosen, what happens when the cancer adapts, and how a treatment taken at home fits with a visit of a few days to Istanbul.

What ALK-positive means

ALK Inhibitor Therapy treats a lung cancer driven by one gene. In ALK-positive lung cancer a piece of chromosome has broken and rejoined in the wrong place, fusing the ALK gene to another gene, most often one called EML4. The fused gene makes a protein that is switched on permanently and tells the cell to grow, and the cancer depends on that signal almost entirely. Block it and the cancer shrinks.

Immunotherapy, which has transformed treatment for many lung cancers, works poorly in ALK-positive disease. That is one more reason the test has to come before the treatment.

Finding the ALK change

Three ways to test

Immunohistochemistry stains the ALK protein on the biopsy slide and gives a result in a day or two. FISH counts whether the gene has broken apart. Sequencing reads many genes at once, ALK, EGFR, ROS1, KRAS and the rest of the drivers that decide treatment in lung cancer, and takes one to three weeks. Every lung adenocarcinoma needs all of them tested before treatment begins. The review checks that yours was.

Five drugs, three generations

Each generation reaches further into the brain and covers more of the mutations that make the cancer resistant. Crizotinib opened the field. Alectinib, brigatinib and lorlatinib are the drugs used first today.

All five are tablets or capsules. None needs a drip, a hospital bed or a day unit.

Choosing the first tablet

Both trials compared the newer drug with crizotinib, the first-generation tablet, and both newer drugs won on every count that mattered. No trial has yet compared alectinib, brigatinib and lorlatinib directly with each other. Choosing between them is a judgment.

The brain

Brain metastases are common in ALK-positive lung cancer, and the newer tablets treat them. In ALEX, 12 percent of patients on alectinib had progression in the brain, against 45 percent on crizotinib, and in CROWN lorlatinib cut the risk of brain progression by 94 percent over five years.

Every patient has a brain MRI at diagnosis. Then at intervals. Small deposits without symptoms are treated with the tablet alone and watched closely. Larger ones, those causing symptoms, or those that keep growing on the tablet are treated with stereotactic radiation, delivered at Biruni Hospital on an Elekta Versa HD linear accelerator, or with surgery. Whole brain radiation is kept for the rare patient in whom nothing else will do, because patients with this cancer may live many years and memory matters.

After surgery for early disease

ALINA

For decades, a patient whose lung cancer was removed completely received four cycles of chemotherapy afterwards to lower the risk of it returning. The ALINA trial, published in the New England Journal of Medicine in 2024, tested two years of alectinib in their place in 257 patients with ALK-positive cancer of stage IB to IIIA removed by surgery.

The risk of the cancer returning fell by three quarters. Survival data were still immature at publication, and the trial compared alectinib with chemotherapy, with no untreated group. Even so, it has made ALK testing of every removed lung adenocarcinoma routine, and two years of alectinib the treatment for ALK-positive disease at these stages.

When the cancer stops responding

Side effects

What each drug tends to cause

Most side effects are managed with a lower dose, and stopping is rarely needed. Changes in mood or thinking on lorlatinib deserve particular attention because the patient tends to be the last to notice them, and a partner or family member who sees a change should say so.

Living on a daily tablet

The tablet is taken every day, for years, at home. Most patients work, travel and look after their families while on it.

A tablet taken at home turns a cancer diagnosis into something closer to a chronic illness for many patients. The work of the treatment moves from the hospital to the kitchen table, and the checks below keep it safe.

Days in Istanbul

Three to five days. Scans, the brain MRI, the molecular report reviewed, a first prescription. Then the tablet goes home with you.

The rest happens at home.

Visits after that

A scan every two to three months is done near home, with the images sent to the oncologist here. Some patients return for their scans. Every three to six months, two or three days. Surgery for early disease means a stay of around two weeks, and stereotactic radiation to the brain adds one to five days to a visit. The coordinator gives you a written plan with the dates.

Flying with the tablets

An ALK inhibitor sets no limit on flying. A patient well enough to walk through an airport is fit to fly home the day after the first visit. Carry the tablets in hand luggage in their original boxes, with the prescription and a letter from the oncologist naming the drug, since customs officers in some countries ask, and keep taking the dose at the same clock time you started with until you are home, then shift it by an hour a day to local time.

What a quote contains

No figure appears here. The tablet is the largest cost by far, month after month, and its price differs from one drug to another and from one country to another.

The consultation, the staging scans, the brain MRI, the molecular test if it has to be repeated, and any radiation are separate lines. Packages published by Turkish hospitals and medical travel agencies for targeted lung cancer treatment cover consultation, scans and the first prescription, and leave out months of the drug, flights, insurance and accommodation.

A quote you can compare names the drug, the number of months it covers and whether the scans are inside the figure. Ask, too, whether your insurer or health system at home pays for the drug once it is prescribed. For many patients that decides where the tablets come from.

Coordinator, language, companion

Companion and paperwork

A companion is welcome.

The office books accommodation close to the hospital and arranges airport transfers and the car to each visit. Ten days or so before travel it issues an appointment confirmation and invitation letter for a visa. The kitchen prepares halal, vegetarian and diabetic meals, a prayer room is on site, and a female physician is arranged where the rota allows for anyone who asks in the first message, which on a short visit like this one should be said early so the rota can be arranged around the dates you have booked.

Follow-up at home

Once you get back home, the treatment runs on the protocol we write, with your own oncologist as the hands and our oncologist as a second pair of eyes.

ALK Inhibitor Therapy FAQ